Ask around Baddi about failed regulatory inspections and buyer audits, and a pattern shows up that has little to do with product quality: the product was fine; the paperwork wasn't. Data-integrity findings — gaps in batch records, transcription mismatches, records that couldn't be traced back to source — have long been among the most common reasons Indian pharma facilities get cited by regulators. Not bad medicine. Bad record-keeping about good medicine.
The root cause is structural
When production happens in one place and documentation happens later, by hand, in another, every batch record is a reconstruction — and reconstructions have errors. Auditors know this, which is why they probe the gap between what happened and what was written down.
The fix is to close that gap at the source: capture production and QC data digitally, once, at the moment it's generated, and let batch records assemble from it. Documentation stops being a separate activity that can drift from reality — it becomes a byproduct of reality. That's the difference between preparing for an audit and simply being ready for one, permanently.
→Map where your records are reconstructed after the fact — each of those points is audit risk.
→Digitize data capture at the source before adding any advanced systems; integrity starts at entry.
→Run your own mock data-integrity audit before a regulator or buyer runs a real one.